Risk Adjusted Net Present Value: What is the current valuation of Roche's Autogene cevumeran

Retrieved on: 2024-09-08 17:44:54

Tags for this article:

Click the tags to see associated articles and topics

Risk Adjusted Net Present Value: What is the current valuation of Roche's Autogene cevumeran. View article details on hiswai:

Excerpt

Autogene cevumeran is a mrna vaccine commercialized by Roche, with a leading Phase II program in Triple-Negative Breast Cancer (TNBC).

Article found on: www.pharmaceutical-technology.com